Announcement on Actual Controller Renewing the Concerted Action Agreement
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Actual Controller Renewing the Concerted Action Agreement
Filed with SSE · · 3 pages · Chinese
Release
Suzhou Zelgen Biopharmaceuticals Co. Ltd. on 6ix
Earlier from Suzhou Zelgen Biopharmaceuticals
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 with Platinum-Containing Chemotherapy Regimen
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZGGS18 and Injectable ZG005 with Chemotherapy Regimen
- Announcement on Voluntary Disclosure of the Approval for Market Launch of Recombinant Human Thyrotropin β for Injection
- Announcement on Conclusion of a Global Strategic Cooperation and License Option Agreement with AbbVie Regarding the Development and Commercialization Rights of ZG006
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
Later from Suzhou Zelgen Biopharmaceuticals
- Earnings Preannouncement for 2025
- Announcement on Shareholding Reduction Plan of Shareholders, Directors and Senior Management Members
- Announcement on Preliminary Earnings Estimate for 2025
- Announcement on Changes of Core Technical Personnel
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
Follow Suzhou Zelgen Biopharmaceuticals into a list and get an email when it puts out news.
Follow Suzhou Zelgen Biopharmaceuticals